The reasons are very absurd such as:
According to a Monday announcement, the decision is due to several factors, including the trial’s complexity and run time. Results weren’t expected to come in until early 2031. Another, ongoing study evaluating the drug in early Parkinson’s patients will continue, with its protocol amended to allow eligible participants from the discontinued trial to enroll.
The Cambridge, MA-based biotech announced Monday morning that it’s discontinuing a Phase III program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics. The study, dubbed LIGHTHOUSE, kicked off in September; it was slated for completion in 2031. Biogen said the decision was made in consideration of the study’s “complexity including the long timeline.”
New Nrf2 activator drug gets FDA approval for Freidrich ataxiaLight Therapy Clinical Trial'I reversed all of my Parkinson's symptoms with one lifestyle change'
Anyone participating in the Buntanetap Phase 3 trial?
New Treatment may be available which could also help men with BPH (benign prostatic hyperplasia)!
